logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jens Bedke

Klinikum Stuttgart
H指数:56
被引数:2.6万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma

TROPION-Urothelial03：达波替安德鲁克坦（Dato-DXd）治疗局部晚期或转移性尿路上皮癌的II/III期研究

Future Oncology
IF2.6
2026-05-160
PRE
Matthew D. Galsky; Alexandra Drakaki; Arnab Basu; Bradley McGregor; Jens Bedke; Yohann Loriot; Eiji Kikuchi; Jun Guo; Benjamin Garmezy; Srikala S. Sridhar; Parminder Singh; Vadim S. Koshkin; Mark Fleming; Gunnar Klauss; Daisy Lin; Chelsea Liu; Andrea B. Apolo; Thomas Powles
Reply to Marcio Covas Moschovas, Mischa Dohler, Mohamad Omar Al Kalaa, and Vipul Patel’s Letter to the Editor re: Bhaskar K. Somani, Jens Rassweiler, Evangelos Liatsikos, et al. European Association of Urology Policy on Telesurgery. Eur Urol 2025;88:318–24

回复Marcio Covas Moschovas, Mischa Dohler, Mohamad Omar Al Kalaa和Vipul Patel致编辑的信函，关于：Bhaskar K. Somani, Jens Rassweiler, Evangelos Liatsikos等人，欧洲泌尿外科学会远程手术政策。Eur Urol 2025;88:318–24

European Urology
IF25.2
2025-12-030
PRE
Bhaskar K. Somani; Jens Rassweiler; Evangelos Liatsikos; Alexandre Mottrie; Thomas Knoll; Jens Bedke; Giampaolo Bianchi; Kemal Sarica; Alberto Briganti; Ton Brouwers; Alberto Breda
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma

CaboPoint：一项关于在转移性肾细胞癌患者中，在基于检查点抑制剂联合疗法之后进行二线卡博替尼治疗的研究

European Urology
IF25.2
2025-09-300
PRE
Laurence Albiges; Thomas Powles; Anand Sharma; Balaji Venugopal; Jens Bedke; Angelika Borkowetz; Gwenaelle Gravis; Berna C. Özdemir; Marco Julius Schnabel; Pascale Dutailly; Bryan Qvick; Valerie Perrot; Viktor Grünwald
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

来自随机III期CheckMate 9ER试验的尼鲁单抗联合卡博赞替尼治疗晚期肾细胞癌的最终分析

Annals of Oncology
IF65.4
2025-09-230
OAAI
R.J. Motzer; B. Escudier; M. Burotto; T. Powles; A.B. Apolo; M.T. Bourlon; A.Y. Shah; C. Porta; C. Suárez; C.H. Barrios; M. Richardet; H. Gurney; E.R. Kessler; Y. Tomita; J. Bedke; C. Scheffold; M. Askelson; J. Panzica; J. Zhang; M. van Kooten Losio; T.K. Choueiri
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

EV-302研究的探索性亚组分析：一项评估恩诺单抗（enfortumab vedotin）联合帕博利珠单抗（pembrolizumab）与化疗对比治疗既往未治疗的局部晚期或转移性尿路上皮癌的III期全球研究

ESMO Open
IF8.3
2025-08-110
OAAI
M.S. van der Heijden; T. Powles; S. Gupta; Y. Loriot; M.D. Galsky; B.P. Valderrama; S.S. Sridhar; E.Y. Yu; G. Iyer; E. Kikuchi; D. Castellano; J. Hoffman-Censits; A. Drakaki; N. Mar; J.P. Maroto Rey; C. Vulsteke; W. Arafat; I. Duran; N.A. Dawson; U. Swami; S. Gorla; B.H. Moreno; X. Yu; Y.-T. Lu; J. Bedke
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

帕博利珠单抗联合阿昔替尼对比舒尼替尼治疗晚期透明细胞肾细胞癌：KEYNOTE-426 III期试验的5年生存率和生物标志物分析

Nature Medicine
IF50
2025-08-010
OA
Brian I. Rini; Elizabeth R. Plimack; Viktor Stus; Rustem Gafanov; Tom Waddell; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Sergio Jobim de Azevedo; Delphine Borchiellini; Raymond S. McDermott; Jens Bedke; Satoshi Tamada; Sterling Wu; Julia Markensohn; Yiwei Zhang; Andrey Loboda; Amir Vajdi; Rodolfo F. Perini; Joseph Burgents; Thomas Powles
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

作者更正: Sasanlimab加BCG在BCG幼稚，高危非肌层浸润性膀胱癌中的应用: 随机3期CREST试验

Nature Medicine
IF50
2025-07-210
OA
Neal D. Shore; Thomas B. Powles; Jens Bedke; Matthew D. Galsky; Joan Palou Redorta; Ja Hyeon Ku; Michal Kretkowski; Evanguelos Xylinas; Boris Alekseev; Dingwei Ye; Félix Guerrero-Ramos; Alberto Briganti; Girish S. Kulkarni; Julia Brinkmann; Anna-Maria Calella; Rossano Cesari; Anthony Eccleston; Elisabete Michelon; Jennifer Vermette; Caimiao Wei; Gary D. Steinberg
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study

肾细胞癌辅助免疫治疗和复发管理的现状：欧洲德尔菲研究的见解

European Journal of Cancer
IF7.1
2025-06-070
PRE
Viktor Grünwald; Axel Bex; Sylvie Rottey; Cristina Suárez; Giuseppe Procopio; Guillermo Velasco; Bohuslav Melichar; Jens Bedke; Lisa Pickering; Mário Fontes-Sousa; Manuela Schmidinger; Aristotelis Bamias; Marine Gross-Goupil; Camillo Porta; Philippe Barthélémy; Bernard Escudier; Laurence Albiges
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial☆

恩诺单抗维多汀联合帕博利珠单抗治疗未经治疗的局部晚期或转移性尿路上皮癌：III期EV-302/KEYNOTE-A39试验的中位2.5年随访结果☆

Annals of Oncology
IF65.4
2025-06-010
PREAI
T.B. Powles; M.S. Van der Heijden; Y. Loriot; J. Bedke; B.P. Valderrama; G. Iyer; E. Kikuchi; J. Hoffman-Censits; C. Vulsteke; A. Drakaki; S. Rausch; W. Arafat; S.H. Park; U. Swami; J.-R. Li; I. Duran; S. Gorla; B. Homet Moreno; X. Yu; Y.-T. Lu; S. Gupta
Hospital Volume as a Determinant of Outcomes After Partial Nephrectomy: A Systematic Review by the European Association of Urology Renal Cell Carcinoma Guidelines Panel

医院手术量作为部分肾切除术预后的决定因素：欧洲泌尿外科学会肾细胞癌指南专家组系统评价

European Urology Oncology
IF9.3
2025-06-010
PRE
Lorenzo Marconi; Teele Kuusk; Milan Hora; Tobias Klatte; Saaed Dabestani; Umberto Capitanio; Yasmin Abu-Ghanem; Riccardo Campi; Sergio Fernández-Pello; Laurence Albiges; Jens Bedke; Thomas Powles; Alessandro Volpe; Börje Ljungberg; Axel Bex
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

恩诺单抗维多汀联合帕博利珠单抗对比化疗在先前未经治疗的局部晚期或转移性尿路上皮癌患者中的疗效（EV-302）：一项开放标签、随机对照、III期研究的患者报告结局

lancet oncology
IF0
2025-05-280
PRE
Shilpa Gupta; Yohann Loriot; Michiel S Van der Heijden; Jens Bedke; Begoña P Valderrama; Eiji Kikuchi; Aude Fléchon; Daniel Petrylak; Maria De Santis; Matthew D Galsky; Jae Lyun Lee; Umang Swami; Srikala S Sridhar; Ugo De Giorgi; Phoebe Wright; Vanessa Shih; Yi-Tsung Lu; Xuesong Guan; Ryan Dillon; Aditya Shetty; Blanca Homet Moreno; Jennifer L Beaumont; Intan Purnajo; Shauna McManus; Thomas Powles
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial

CheckMate 901试验中，仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合吉西他滨-顺铂治疗与单独吉西他滨-顺铂治疗的特征分析

European Urology
IF25.2
2025-05-200
OAAI
Matthew D. Galsky; Michiel S. van der Heijden; Thomas Powles; Melanie Claps; Mauricio Burotto; Michael Schenker; Juan Pablo Sade; Aristotelis Bamias; Philippe Beuzeboc; Jens Bedke; Jan Oldenburg; Yüksel Ürün; Dingwei Ye; Begoña P. Valderrama; Yoshihiko Tomita; Ruiyun Jiang; Jeiry Filian; Lily Wang; Maximiliano van Kooten Losio; Guru Sonpavde
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa

开放手术与机器人辅助部分肾切除术在中等/高复杂性肾肿瘤患者中的应用比较：随机、对照、开放标签、多中心试验OpeRa的最终结果

Annals of Oncology
IF65.4
2025-04-160
OAAI
M.-O. Grimm; J. Bedke; J. Nyarangi-Dix; W. Khoder; S. Foller; H.-J. Sommerfeld; M. Giessing; M. Heck; W. Meißner; A. Slee; K. Leucht; F. von Rundstedt; G. Theil; S. Buse; S. Siemer; P. Albers; C. Gratzke; M. Hohenfellner; A. Stenzl
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

非透明细胞肾细胞癌中，伊匹木单抗/纳武利尤单抗对比标准护理的 prospective randomized phase-II trial - SUNNIFORECAST trial 的结果

Annals of Oncology
IF65.4
2025-04-010
OA
L. Bergmann; L. Albiges; M. Ahrens; M. Gross-Goupil; E. Boleti; G. Gravis; A. Fléchon; M.-O. Grimm; J. Bedke; P. Barthélémy; D. Castellano; B. Mellado; P. Ivanyi; S. Rottey; A. Flörcken; C. Suarez; P. Maroto; V. Grünwald; S.F. Oosting; J. Kopecky; S. Zschäbitz; M. Boegemann; T. Buchler; G. Niegisch; P.J. Goebell; T. Waddell; F. Joly; F. Priou; M. Retz; S. Siemer; U. Zimmermann; D. Deckbar; I. Burkholder; A. Hartmann; J.B. Haanen

研究方向

暂未获取到该数据
A
Arnulf Stenzl
H 指数:87论文数:1,627被引数:3.6万
S
Steffen Rausch
H 指数:27论文数:213被引数:2,459
T
Thomas Powles
H 指数:77论文数:689被引数:3.6万
S
Stephan Kruck
H 指数:0论文数:0被引数:0
M
Matthias Schwab
H 指数:122论文数:1,356被引数:7.0万
J
Jörg Hennenlotter
H 指数:44论文数:363被引数:6,456
E
Elke Schaeffeler
H 指数:63论文数:317被引数:1.4万
M
Marcus Scharpf
H 指数:27论文数:174被引数:2,035
S
Stefan Winter
H 指数:45论文数:229被引数:7,538
L
Laurence Albigès
H 指数:83论文数:1,027被引数:3.7万